<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002647</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064165</org_study_id>
    <secondary_id>MCW-7594</secondary_id>
    <secondary_id>MCW-CHW-511</secondary_id>
    <secondary_id>MCW-CHW-9411</secondary_id>
    <secondary_id>NCI-V95-0652</secondary_id>
    <nct_id>NCT00002647</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors</brief_title>
  <official_title>Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and
      may be an effective treatment for refractory brain tumors.

      PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic
      therapy using porfimer sodium in treating patients with refractory brain tumors, including
      astrocytoma, ependymoma, and medulloblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of benzoporphyrin monoacid ring A in patients with
           refractory brain tumors undergoing cavitary photoillumination photodynamic therapy.

        -  Determine the effect of this regimen on neurotoxicity, clinical state, imaging changes,
           and survival of these patients.

      OUTLINE: This is a dose-escalation study. Patients are stratified according to tumor location
      (posterior fossa tumors vs all other brain tumors).

      Patients receive benzoporphyrin monoacid ring A (BPD-MA) IV preoperatively. Approximately 3
      hours after BPD-MA administration, patients undergo craniotomy with photoillumination of the
      tumor. Patients with tumors greater than 2 cm in diameter also undergo gross tumor resection.

      Cohorts of 3-6 patients receive escalating doses of BPD-MA until the maximum tolerated dose
      (MTD) is determined. The MTD is defined as the dose immediately preceding that at which 2 of
      3 or 2 of 6 patients experience dose-limiting toxicity. Three additional patients are treated
      at the MTD.

      Patients are followed at 4 and 6 weeks, every 3 months for 1 year, every 6 months for 1 year,
      and then annually thereafter.

      PROJECTED ACCRUAL: A minimum of 24 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 1994</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of supratentorial or infratentorial brain tumor

               -  Localized, non-disseminated

               -  Primary tumor or solitary metastasis

               -  Recurrent or progressive

               -  Unresectable

               -  Negative CSF

          -  Must have failed standard therapy including radiotherapy

          -  Measurable disease as evidenced by CT scan or MRI

               -  Single or multiple masses accessible to light administration

        PATIENT CHARACTERISTICS:

        Age:

          -  3 to 70

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm3

          -  May transfuse platelets

        Hepatic:

          -  PT and PTT normal

        Renal:

          -  Not specified

        Other:

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 6 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior brachytherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No other concurrent antitumor therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry T. Whelan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Medical College of Wisconsin Cancer C</last_name>
      <phone>414-805-4380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce A. Kaufman, MD</last_name>
      <phone>414-266-2000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schmidt MH, Bajic DM, Reichert KW 2nd, Martin TS, Meyer GA, Whelan HT. Light-emitting diodes as a light source for intraoperative photodynamic therapy. Neurosurgery. 1996 Mar;38(3):552-6; discussion 556-7.</citation>
    <PMID>8837808</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood diffuse astrocytoma</keyword>
  <keyword>recurrent childhood fibrillary astrocytoma</keyword>
  <keyword>recurrent childhood gemistocytic astrocytoma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>recurrent childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood pilocytic astrocytoma</keyword>
  <keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
  <keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
  <keyword>recurrent childhood protoplasmic astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic meningioma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>meningeal melanocytoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult papillary meningioma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

